Identifying Inflammatory Biomarkers of Chronic Obstructive Pulmonary Disease
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 12/8/2017 |
| Start Date: | July 2006 |
| End Date: | January 2013 |
Serum Inflammatory Biomarkers as Predictors of COPD Morbidity and Mortality
Chronic obstructive pulmonary disease (COPD) is a condition that is characterized by airway
obstruction due to inflammation. Levels of inflammatory proteins may be linked to when and to
what extent COPD develops. This study will use data collected during the Tucson
Epidemiological Study of Airway Obstructive Disease (TESAOD) and its 33-year follow-up to
determine the relationship between inflammatory protein expression and COPD.
obstruction due to inflammation. Levels of inflammatory proteins may be linked to when and to
what extent COPD develops. This study will use data collected during the Tucson
Epidemiological Study of Airway Obstructive Disease (TESAOD) and its 33-year follow-up to
determine the relationship between inflammatory protein expression and COPD.
COPD is a term that encompasses both chronic bronchitis and emphysema, two diseases that are
characterized by airway obstruction that interferes with normal breathing. Airway
inflammation can stem from exposure to harmful fumes in the air, chronic bacterial infections
in the airways, and a genetic predisposition to an inflammatory response to these agents. In
people with COPD, the airway inflammation may extend beyond the lungs and contribute to
systemic symptoms and, ultimately, to an increased mortality risk. Markers of systemic
inflammation have been identified, but the relationship between these markers and when and to
what extent COPD develops has not been determined. This study will use data collected during
the TESAOD and its 33-year follow-up to determine the relationship between COPD and the
expression of various inflammatory proteins, including pro-inflammatory cytokines (e.g.,
IL-6, IL-8, TNF-alpha) and acute phase proteins (e.g., C-reactive protein, soluble CD14).
This study will not recruit any new participants. Detailed respiratory phenotypic information
and serum samples that were collected during the TESAOD study will be evaluated in
conjunction with newly generated biomarker and protein information. No new phenotypic data or
biological specimens will be collected in this study.
characterized by airway obstruction that interferes with normal breathing. Airway
inflammation can stem from exposure to harmful fumes in the air, chronic bacterial infections
in the airways, and a genetic predisposition to an inflammatory response to these agents. In
people with COPD, the airway inflammation may extend beyond the lungs and contribute to
systemic symptoms and, ultimately, to an increased mortality risk. Markers of systemic
inflammation have been identified, but the relationship between these markers and when and to
what extent COPD develops has not been determined. This study will use data collected during
the TESAOD and its 33-year follow-up to determine the relationship between COPD and the
expression of various inflammatory proteins, including pro-inflammatory cytokines (e.g.,
IL-6, IL-8, TNF-alpha) and acute phase proteins (e.g., C-reactive protein, soluble CD14).
This study will not recruit any new participants. Detailed respiratory phenotypic information
and serum samples that were collected during the TESAOD study will be evaluated in
conjunction with newly generated biomarker and protein information. No new phenotypic data or
biological specimens will be collected in this study.
Inclusion Criteria:
- Enrolled in the Tucson Epidemiological Study of Airway Obstructive Disease (TESAOD)
We found this trial at
1
site
Click here to add this to my saved trials
